<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107923</url>
  </required_header>
  <id_info>
    <org_study_id>535444</org_study_id>
    <nct_id>NCT03107923</nct_id>
  </id_info>
  <brief_title>Better Patient Selection to Transcatheter Aortic Valve Implantation</brief_title>
  <official_title>Better Patient Selection to Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether a preoperative assessment of myocardial contractile reserve by
      tissue Doppler Imaging and myocardial fibrosis by cardiac magnetic resonance imaging (MRI)
      can enhance the patient selection and risk stratification to transcatheter aortic valve
      implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observation study we will investigate whether a preoperative test of
      myocardial contractile reserve can predict adverse outcome after TAVI. We intend to examine
      preoperative myocardial contractile reserve by use a low dose dobutamine test and relate this
      to pre-existing myocardial focal and diffuse myocardial fibrosis detected by new cardiac
      magnetic resonance imaging (MRI) methods and new echocardiographic methods. These measures
      will be primarily related to long term (12 months) mortality.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 26, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality at 12 months follow-up after TAVI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac morbidity</measure>
    <time_frame>1 year</time_frame>
    <description>Hospitalization for heart related diseases.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>SF 36</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>1 year</time_frame>
    <description>Dimensions, and systolic and diastolic function</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Myocardial Fibrosis</condition>
  <arm_group>
    <arm_group_label>Preoperative myocardial reserve yes/no</arm_group_label>
    <description>Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dobutamine stress test</intervention_name>
    <description>Test of myocardial reserve</description>
    <arm_group_label>Preoperative myocardial reserve yes/no</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for transfemoral aortic valve implantation at Oslo University
        Hospital-Rikshospitalet
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients declined surgical aortic valve replacement and scheduled for transfemoral
             aortic valve implantation.

        Exclusion Criteria:

          -  Aortic valve endocarditis

          -  aortic annulus &gt;31mm

          -  preoperative pacemaker

          -  severe aortic insufficiency (&gt;grad 3)

          -  rapid atrial fibrillation

          -  unprotected left main coronary stenosis not suitable for percutaneous intervention.

          -  unstable angina

          -  life expectancy less than 12 months

          -  mental disorder including dementia and condition which interferes with protocol
             compliance.

          -  renal failure (glomerular filtration rate &lt; 45 ml/min/m2), only have T1 mapping by
             CMRI.

          -  Patients with metal not suitable for MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erik Fosse, Professor</last_name>
    <phone>+4723070100</phone>
    <email>erik.fosse@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Intervention Centre, Oslo Universtity Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Per Steinar Halvorsen, MD, PhD</last_name>
      <phone>+4746431499</phone>
      <email>sthalvor@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Jan Otto Beitnes, MD, PhD</last_name>
      <phone>+4792022152</phone>
      <email>jbeitnes@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Bax JJ, Delgado V, Bapat V, Baumgartner H, Collet JP, Erbel R, Hamm C, Kappetein AP, Leipsic J, Leon MB, MacCarthy P, Piazza N, Pibarot P, Roberts WC, Rod√©s-Cabau J, Serruys PW, Thomas M, Vahanian A, Webb J, Zamorano JL, Windecker S. Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation. Eur Heart J. 2014 Oct 7;35(38):2627-38. doi: 10.1093/eurheartj/ehu256. Epub 2014 Jul 25. Review.</citation>
    <PMID>25062952</PMID>
  </reference>
  <reference>
    <citation>Eidet J, Dahle G, Bugge JF, Bendz B, Rein KA, Aaberge L, Offstad JT, Fosse E, Aakhus S, Halvorsen PS. Long-term outcomes after transcatheter aortic valve implantation: the impact of intraoperative tissue Doppler echocardiography. Interact Cardiovasc Thorac Surg. 2016 Sep;23(3):403-9. doi: 10.1093/icvts/ivw159. Epub 2016 May 30.</citation>
    <PMID>27241050</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Per Steinar Halvorsen</investigator_full_name>
    <investigator_title>Consultant and research group leader</investigator_title>
  </responsible_party>
  <keyword>Myocardial fibrosis</keyword>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>TAVI</keyword>
  <keyword>Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

